Renalytix presents new clinical data on KidneyIntelX

Renalytix announced the presentation of new clinical data for ‘KidneyIntelX’ bioprognostic testing at the World Congress of Nephrology’s annual meeting on Thursday.

The AIM-traded firm said the results provided “robust” prognostic information, demonstrating the value of KidneyIntelX to predict the future rate of decline in kidney function compared with current standard diagnostics in patients with early-stage chronic kidney disease and type-2 diabetes.

It said that included estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (UACR), and eGFR slope.

The board said advanced risk assessment tools, such as KidneyIntelX, enabled primary care physicians to make “optimised” treatment decisions through accurate determination of individual patient risk, and provide the opportunity to change intensity of care management based on that risk.

In the short term, KidneyIntelX could more efficiently assess the integrated impact of changes in key risk factors - glucose, blood pressure and albuminuria - on overall kidney health, which often did not manifest in kidney function improvements for several years.

The company said the data also showed the ability to use KidneyIntelX in conjunction with clinical features to reinforce the beneficial effects of new therapeutics in the same population.

“Enabling optimal pharmacy management via KidneyIntelX may ultimately decrease hospital admissions, emergency room visits, dialysis and kidney failure risks,” said company president Tom McLain.

“Most importantly, KidneyIntelX can help improve the quality of life for patients by enabling primary care physicians to mitigate risk at the earliest stages of kidney disease.”

At 1259 GMT, shares in Renalytix were down 9.85% at 302p.